PLRX Nasdaq 2019 - 07 - 17

Pliant Therapeutics, Inc.

PLRX | $12.105 -0.7% 37K

(0.0% 1d) (-18.2% 1m) (-58.2% 1y) (0.0% 2d) (-5.2% 3d) (-10.0% 7d) (33.68% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 729,195,225
http://www.pliantrx.com
Sec Filling | Patents | 62 employees

(US) Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

add to watch list Paper trade email alert is off

Press-releases

Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight
Published: 2024-04-03 (Crawled : 22:00) - prnewswire.com
PLRX | $12.105 -0.7% 37K

Health Technology

| -15.52% | O: 1.87% H: 3.4% C: -1.02%
fibrosis therapeutics growth market

Pliant Therapeutics to Participate in Upcoming Investor Events
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
PLRX | $12.105 -0.7% 37K

Health Technology

| -16.51% | O: -0.62% H: 1.17% C: 1.17%
therapeutics

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
Published: 2024-03-27 (Crawled : 14:30) - globenewswire.com
PLRX | $12.105 -0.7% 37K

Health Technology

| -13.79% | O: 1.34% H: 3.63% C: 1.54%
conference international therapeutics

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PLRX | $12.105 -0.7% 37K

Health Technology

| -16.1% | O: 0.0% H: 6.88% C: 4.2%
treatment fibrosis bexotegrast therapeutics

Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
Published: 2024-03-12 (Crawled : 17:00) - biospace.com/
PLRX | $12.105 -0.7% 37K

Health Technology

| -16.1% | O: 0.0% H: 6.88% C: 4.2%
MRKR | $4.1002 2.1K

Consumer Services

| 4.11% | O: -1.2% H: 4.88% C: 3.17%
therapeutics

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
Published: 2024-02-27 (Crawled : 21:00) - globenewswire.com
PLRX | $12.105 -0.7% 37K

Health Technology

| -29.17% | O: 4.59% H: 0.0% C: -7.67%
update therapeutics financial results

Pliant Therapeutics to Participate in Upcoming Investor Conferences
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
PLRX | $12.105 -0.7% 37K

Health Technology

| -25.81% | O: -0.3% H: 4.27% C: 1.4%
therapeutics

Pliant Therapeutics to Participate in Upcoming Investor Events - February 7, 2024
Published: 2024-02-07 (Crawled : 15:00) - biospace.com/
PLRX | $12.105 -0.7% 37K

Health Technology

| -24.33% | O: 0.0% H: 0.93% C: -0.87%
therapeutics

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2024-02-04 (Crawled : 00:00) - globenewswire.com
PLRX | $12.105 -0.7% 37K

Health Technology